DPDavid Pryor

David Pryor

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David Pryor has a total of 350 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • ENZARAD (ANZUP 1303): Phase 3 Trial of Enzalutamide With Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate Cancer

    by Scott Williams, Christopher J. Sweeney, Hayley Thomas, Blossom Mak, Alison Zhang, Tee Sin Lim, Chakiath Jose, Jarad Martin, Nitya Patanjali, David Pryor, et al.

    Background: The effects of adding enzalutamide to androgen deprivation therapy (ADT) and radiotherapy for high-risk localized or locally advanced prostate cancer were unknown. Methods: Open-label, phase 3 trial of definitive prostate radiotherapy with 24 months of ADT and 1:1 randomization to either enzalutamide (160mg daily for 24 months) or an older nonsteroidal antiandrogen (NSAA) for 6 months. The primary endpoint was metastasis-free survival on conventional imaging (MFS-CI) with computerized tomography and/or 99m Tc-bone scintigraphy. Radiation to pelvic lymph nodes was required for cN1 disease but optional for cN0. Results: 802 participants were randomized. After a median follow-up of 92 months, 207 MFS-CI events were reported (98 enzalutamide, 109 NSAA) with 8-year MFS-CI rates 74% vs 72%, hazard ratio [HR] 0.88, 95% confidence interval [CI], 0.67 to 1.15; P =0.34). Prespecified subgroup analyses noted enzalutamide was associated with a possible MFS-CI benefit in the subgroup undergoing planned pelvic nodal radiotherapy, N=324 (HR 0.47, 95% CI: 0.29 to 0.76 P adjusted =0.004). Grade 3-5 adverse events were reported in 185 participants in each arm. Conclusions: The use of enzalutamide rather than NSAA in addition to radiotherapy and ADT for 2 years showed no significant MFS-CI or OS improvement at 8 years.

  • Salvage stereotactic ablative body radiotherapy after thermal ablation of primary kidney cancer

    by Muhammad Ali, Young Suk Kwon, Kendrick Koo, Anna Bruynzeel, David Pryor, Daniel G. Schep, Michael Huo, Maggie Stein, Anand Swaminath, Raquibul Hannan, et al.

    Objective: To evaluate the effectiveness and safety of salvage stereotactic ablative body radiotherapy (SABR) for recurrent renal cell carcinoma (RCC) after thermal ablation (TA). Materials and Methods: This study was a multi‐institutional retrospective analysis of patients with recurrent RCC following TA who received SABR between 2016 and 2020. The primary study outcome was freedom from local failure, evaluated radiographically based on Response Evaluation Criteria in Solid Tumours (RECIST) v1.1. Distant failure, cancer‐specific survival (CSS), overall survival (OS), treatment‐related toxicity and renal function changes following SABR were the secondary outcomes. The Kaplan–Meier method was used to estimate freedom from local and distant failure, CSS and OS. Results: Seventeen patients with 18 biopsy‐confirmed RCCs were included, with a median (interquartile range [IQR]) age at time of SABR of 75.2 (72.6–68.7) years, a median (IQR) tumour size of 3.5 (1.9–4.1) cm and follow‐up (reverse Kaplan–Meier method) of 3.36 (95% confidence interval [CI] 1.6–4.1) years. Six of the 17 patients had a solitary kidney. Five patients had failed repeat TA prior to SABR. The median (IQR) time from TA procedure to SABR was 3.03 (1.5–5.1) years. No patient experienced local progression, with a local control rate of 100%. Four patients, two with baseline metastatic disease, experienced distant progression. The distant progression‐free survival, CSS and OS at 3 years were 72.1% (95% CI 51.9%–100%), 92.3% (95% CI 78.9%–100%) and 82.1% (95% CI 62.1%–100%), respectively. The median (IQR) glomerular filtration rate before SABR was 58 (40–71) mL/min, and at last follow‐up, it was 48 (33–57) mL/min. No patient experienced grade 3+ toxicity or went on to develop end‐stage renal disease. Conclusion: The results showed that SABR appears to be an effective and safe salvage strategy in patients with recurrent RCC following TA.


  • Barriers and enablers of active surveillance for prostate cancer: a qualitive study of clinicians

    by Trent A. Pattenden, Isaac A. Thangasamy, Wee Loon Ong, Dhanika Samaranayke, Andrew Morton, Declan G. Murphy, Sue Evans, Jeremy Millar, Venu Chalasani, Prem Rashid, et al.

    Objectives: To identify and explore barriers to, and enablers of, active surveillance (AS) in men with low‐risk prostate cancer (LRPCa), as perceived by PCa clinicians. Patients and Methods: Urologists and radiation oncologists in Australia and New Zealand were purposively sampled for a cross‐section on gender and practice setting (metropolitan/regional; public/private). Using a grounded theory approach, semi‐structed interviews were conducted with participants. Interviews were coded independently by two researchers using open, axial, and selective coding. A constant comparative approach was used to analyse data as it was collected. Thematic saturation was reached after 18 interviews, and a detailed model of barriers to, and enablers of, AS for LRPCa, as perceived by clinicians was developed. Results: A model explaining what affects clinician decision making regarding AS in LRPCa emerged. It was underpinned by three broad themes: (i) clinician perception of patients’ barriers and enablers; (ii) clinician perception of their own barriers and enablers; and (iii) engagement with healthcare team and resource availability. Conclusions: Clinicians unanimously agree that AS is an evidence‐based approach for managing LRPCa. Despite this many men do not undergo AS for LRPCa, which is due to the interplay of patient and clinician factors, and their interaction with the wider healthcare system. This study identifies strategies to mitigate barriers and enhance enablers, which could increase access to AS by patients with LRPCa.


  • Definitive Stereotactic Body Radiation Therapy in Early-Stage Solitary Hepatocellular Carcinoma: An Australian Multi-Institutional Review of Outcomes

    by H.Y.-H. Liu, Y.-Y.D. Lee, S. Sridharan, W. Wang, R. Khor, J. Chu, A. Oar, E.S. Choong, H. Le, M. Shanker, et al.


  • Open Access

    NeoAdjuvant pembrolizumab and STEreotactic radiotherapy prior to nephrectomy for renal cell carcinoma (NAPSTER): A phase II randomised clinical trial

    by Muhammad Ali, Simon Wood, David Pryor, Daniel Moon, Mathias Bressel, Arun A. Azad, Catherine Mitchell, Declan Murphy, Homi Zargar, Nick Hardcastle, et al.


  • Refining stereotactic body radiation therapy as a bridge to transplantation for hepatocellular carcinoma: An institutional experience

    by Beini Chen, Nick Butler, Thomas O'ROurke, Peter Hodgkinson, Katherine Stuart, Edwin Shih, David Leggett, David Pryor, Howard Liu, Dominique Lee

    Background: Stereotactic body radiotherapy (SBRT) has been established as a safe and effective treatment for hepatocellular carcinoma (HCC). Currently, there are no consensus guidelines to advise optimal patient selection and radiotherapy planning parameters to minimise the risk of surgical and medical complications after liver transplant (LT) in patients who have had prior SBRT for HCC, whilst optimising treatment benefit.Methods: We performed a retrospective analysis of all adult patients who received liver SBRT as a bridge to LT at a tertiary institution between 2017 and 2019.Results: Nine patients received SBRT as bridging therapy to LT. HCC location varied from peripheral to central/hilar regions and HCC diameter was 13–54 mm. Median time between SBRT and LT was 141 days (range 27–461 days). Median operating time was 360 min (range 270–480 min). Four patients (44%) had visible SBRT reaction or fibrosis at the time of LT. SBRT reaction resulted in clinical impact in one patient (11%) only, where vascular clamping of the IVC was required for 10 min.Conclusion: SBRT is a safe and effective treatment for HCC enabling patients to remain within LT criteria, even for lesions not amenable to other more conventional bridging therapies. We describe a preliminary decision pathway to guide the optimal use of SBRT as a bridge to LT developed in our institution.


  • Open Access

    Large variation in conservative management of low‐risk prostate cancer in Australia and New Zealand

    by Wee Loon Ong, Isaac Thangasamy, Declan Murphy, Elizabeth Pritchard, Susan Evans, Jeremy Millar, Venu Chalasani, Prem Rashid, Matthew Winter, Ian Vela, et al.


  • Assessment of HDR brachytherapy-replicating prostate radiotherapy planning for tomotherapy, cyberknife and VMAT

    by Romena de Chavez, Garry Grogan, Ben Hug, Kate Howe, Alice Grigg, David Waterhouse, Jonathan Lane, Alan Glyde, Elizabeth Brown, Sean Bydder, et al.


  • Open Access

    Evaluation of Hypofractionated Radiation Therapy Use and Patient-Reported Outcomes in Men With Nonmetastatic Prostate Cancer in Australia and New Zealand

    by David I. Pryor, Jarad M. Martin, Jeremy L. Millar, Heather Day, Wee Loon Ong, Marketa Skala, Liesel M. FitzGerald, Benjamin Hindson, Braden Higgs, Michael E. O’cAllaghan, et al.

    Level 1 evidence supports shorter fractionation schedules for men with prostate cancer receiving external beam radiation therapy (EBRT). In 2016 and early 2017, 3 large randomized clinical trials reported noninferiority of cancer control, toxic effects, and patient-reported outcomes (PROs) for short-course moderately hypofractionated EBRT (HRT) compared with long-course conventional radiation therapy (CRT).1-3 The 2018 American Society for Radiation Oncology, American Society of Clinical Oncology, and American Urological Association guideline update4 recommended that HRT be offered for any localized prostate cancer risk category when using EBRT and not treating the pelvic lymph nodes.


  • Automatic radiotherapy delineation quality assurance on prostate MRI with deep learning in a multicentre clinical trial

    by Hang Min, Jason Dowling, Michael G Jameson, Kirrily Cloak, Joselle Faustino, Mark Sidhom, Jarad Martin, Martin A Ebert, Annette Haworth, Phillip Chlap, et al.

    Volume delineation quality assurance (QA) is particularly important in clinical trial settings where consistent protocol implementation is required, as outcomes will affect future as well current patients. Currently, where feasible, this is conducted manually, which is time consuming and resource intensive. Although previous studies mostly focused on automating delineation QA on CT, magnetic resonance imaging (MRI) is being increasingly used in radiotherapy treatment. In this work, we propose to perform automatic delineation QA on prostate MRI for both the clinical target volume (CTV) and organs-at-risk (OARs) by using delineations generated by 3D Unet variants as benchmarks for QA. These networks were trained on a small gold standard atlas set and applied on a multicentre radiotherapy clinical trial dataset to generate benchmark delineations. Then, a QA stage was designed to recommend ‘pass’, ‘minor correction’ and ‘major correction’ for each manual delineation in the trial set by thresholding its Dice similarity coefficient to the network generated delineation. Among all 3D Unet variants explored, the Unet with anatomical gates in an AtlasNet architecture performed the best in delineation QA, achieving an area under the receiver operating characteristics curve of 0.97, 0.92, 0.89 and 0.97 for identifying unacceptable (major correction) delineations with a sensitivity of 0.93, 0.73, 0.74 and 0.90 at a specificity of 0.93, 0.86, 0.86 and 0.95 for bladder, prostate CTV, rectum and gel spacer respectively. To the best of our knowledge, this is the first study to propose automated delineation QA for a multicentre radiotherapy clinical trial with treatment planning MRI. The methods proposed in this work can potentially improve the accuracy and consistency of CTV and OAR delineation in radiotherapy treatment planning.